100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- March Biosciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback